Skip to content

Sedative Premedication: Efficacy On Patient Experience

SEDATIVE PREMEDICATION: EFFICACY ON PATIENT EXPERIENCE

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01901003
Acronym
PremedX
Enrollment
1200
Registered
2013-07-17
Start date
2012-11-30
Completion date
2014-06-30
Last updated
2015-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative Anxiety

Brief summary

Seven French university hospitals will participate in this multicentric prospective, blinded and randomized study. The investigators designed 3 study groups: Lorazepam 2.5mg, Placebo (microcrystalline celluloses) and no premedication at all. The third group (no premedication) is necessary in order to evaluate a placebo response, which may be significant on anxiety level and patients perceptions of care. It was calculated that 969 patients had to be included in order to obtain a 5 point difference between groups on the EVAN score with 80 % statistical power, leading to the inclusion of 1200 patients with an estimated maximum dropout rate of 15 %. All adults below 70 years and scheduled for elective surgery under general anesthesia can be included after information by an anesthesiologist in charge of the study and written informed consent. Non inclusion criterions are: a weight below 45 Kg, a counter indication to benzodiazepine, surgeries that could impair cognitive functions (cardiac or neurologic surgery), usual use of neuroleptics or lithium, drug addiction or former cognitive disease. The technique of anesthesia will be decided by the attending anesthesiologist, who will be unaware of the premedication technique, independently of the study protocol.

Interventions

DRUGLorazepam
DRUGPlacebo (microcrystalline celluloses)

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* male or female aged 18 to 70 years or more; * About a weight greater than 45 kg; * Subject to benefit from a scheduled surgery under general anesthesia; * Topic respecting the ambivalence clause defined below: 1. Having no cons-indication to the use of benzodiazepines; 2. Having no known allergy to benzodiazepines; 3. May be a candidate for the prescription of premedication; * Topic able to complete a self-administered questionnaire; * Subject has signed a written informed consent and agreeing to abide by the instructions of the Protocol

Exclusion criteria

* \- Topic of over 70 years; * Topic 45 kg or less; * Topic demanding to receive anxiolytic premedication; * Subject severe respiratory insufficiency; * Topic minor, pregnant or breastfeeding, about not being affiliated to the social security system; * Topic for which surgery is performed under local anesthesia; * Subject unable to perform only a self-administered questionnaire (inability to read French, severe cognitive impairment); * Subject to which the scheduled surgery may cause postoperative cognitive dysfunction (intracranial surgery, extracorporeal circulation); * Topic scheduled for obstetrical surgery or outpatient; * Subject treated with antipsychotic (neuroleptic or lithium); * Subject with cognitive impairment already documented (Alzheimer, dementia, neurological sequelae); * Subject active consumer of narcotics; * Subject has not signed informed consent.

Design outcomes

Primary

MeasureTime frameDescription
the EVAN score2 yearsto evaluate patient satisfaction of the perioperative period

Secondary

MeasureTime frameDescription
the perioperative level of anxiety2 yearsAPAIS score (Moerman 1996) before surgery

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026